$Viking Therapeutics (VKTX.US)$ VKTX [Why did it drop] -16%,...
$Viking Therapeutics(VKTX.US$ VKTX [Why did it drop] -16%, as its competitor drug giant NVO Novo Nordisk will launch the obesity drug Wegovy in Japan to address Japan's growing weight problem. Novo Nordisk's chief strategy officer said earlier at the Capital Markets Day event that the first phase of the trial of the experimental drug Amycretin (Amycretin) showed participants lost 13.1% of their body weight after 12 weeks. Investors were thrilled. Additionally, the agency Jefferies gave a purchase evaluation of Viking Therapeutics, with a target price of $110.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
